Searchable abstracts of presentations at key conferences in endocrinology

ea0019p136 | Diabetes, Metabolism and Cardiovascular | SFEBES2009

Susceptibility to hyperinsulinaemia and fatty liver with loss of 5alpha-reductase 1 occurs in rats and mice and is not androgen dependent

Livingstone D , Walker B , Andrew R

5alpha-Reductase 1 (5aR1) catalyses A-ring reduction of glucocorticoids and androgens. We previously demonstrated that transgenic disruption of 5aR1 predisposes male mice to fatty liver and insulin resistance when challenged with a high-fat diet. Here, we have dissected the contributions of androgens and glucocorticoids to the metabolic phenotype using 2 models of enzyme inhibition (trangenesis and pharmacology).Female 5aR1−/− mice (KO) and w...

ea0007p204 | Steroids | BES2004

Inhibition of steroid 5beta-reductase by bile acids

McNeilly A , Livingstone D , Walker B , Andrew R

Hepatic A-ring reduction of glucocorticoids is enhanced in obesity, perhaps contributing to compensatory activation of the hypothalamic-pituitary-adrenal axis and adrenal androgen excess. One pathway activated is the formation of tetrahydro metabolites by two sequential steps catalysed by 5beta-reductase (5bR) followed by 3alpha-hydroxysteroid dehydrogenases (3HSD). However, regulation of these enzymes is understood poorly. 5bR and 3HSD are also involved in the conversion of c...

ea0009oc33 | Oral Communication 4: Steroids | BES2005

Generation of glucocorticoids by 11beta-hydroxysteroid dehydrogenase isozymes in the perfused mouse hindlimb

Dover A , Hadoke P , Miller E , Newby D , Walker B

Glucocorticoids (cortisol in man, corticosterone in rodents) can inhibit angiogenesis, alter contractile function and reduce the inflammatory response to injury in the vascular wall. These effects are regulated by the 11beta-hydroxysteroid dehydrogenases (11HSDs) which inter-convert active glucocorticoids and their inactive 11-keto metabolites (cortisone; 11-dehydrocorticosterone) within target tissues. 11HSD2 is a unidirectional, exclusive dehydrogenase which inactivates gluc...

ea0007p19 | Comparative endocrinology | BES2004

Changes in bone mineral density in response to growth hormone replacement in adults with isolated growth hormone deficiency compared with multiple pituitary hormone deficiencies

Waterhouse M , Loureiro R , Walker D , Besser G , Monson J

The contribution of conventional hormone replacement to the clinical features attributed to adult growth hormone deficiency (GHD) is poorly defined. We measured baseline bone mineral density (BMD/DXA) at the lumbar spine and femoral neck in patients with isolated GHD (IGHD, 16 patients, 14 female, 4 childhood onset, mean age 39, range 19- 63 years) and patients with multiple pituitary hormone deficiencies (MPD, 135 patients, 94 female, 14 childhood onset, mean age 44, range 19...

ea0006p18 | Cytokines | SFE2003


Hyatt M , Walker D , Stephenson T , Symonds M

Maternal nutrient restriction (NR) during late-gestation can influence liver growth by altering maturation of the hypothalamus. Maternal NR during late-gestation increases fetal plasma GH levels whilst circulating IGF-I and IGF-II levels decrease. This study aimed to determine whether maternal NR during late-gestation altered the hepatic IGF system in resultant offspring.Fourteen primiparous twin pregnant Border Leicester cross Swaledale ewes were fed <i...

ea0005p91 | Diabetes, Metabolism and Cardiovascular | BES2003

Baseline clinical characteristics and response to growth hormone replacement therapy in adults with isolated growth hormone deficiency in comparison with multiple pituitary hormone deficiencies

Waterhouse M , Loureiro R , Walker D , Besser G , Monson J

The contribution to adult growth hormone deficiency (GHD) of hormone replacement and other aspects of hypopituitarism are poorly defined. We compared baseline characteristics and response to GH treatment of patients with isolated GHD (IGHD, 16 patients) to patients with multiple pituitary hormone deficiencies (MPD, 135 patients). At baseline, MPD patients showed significantly greater waist-hip ratios (0.87 plus/minus 0.007 vs. 0.82 plus/minus 0.02, mean plus/minus SD; P < 0...

ea0005p184 | Neuroendocrinology and Behaviour | BES2003

Differential effects of the route of testosterone administration on GH sensitivity and bone mineral density in hypopituitarism

Brooke A , Carroll P , Walker D , Besser G , Monson J

The route of oestrogen replacement has an important influence on growth hormone (GH) sensitivity, but it remains unclear whether the route of testosterone treatment in hypopituitarism influences the response to GH replacement. We have compared IGF-I levels, body composition and BMD in hypopituitary male patients with severe GH-deficiency receiving either oral testosterone undecanoate (T.U.)(80-160 milligrams per day) or intramuscular testosterone (I.M.) (250-500 milligrams per...

ea0029p1427 | Pituitary Clinical | ICEECE2012

Control of GH and IGF1 in acromegaly in the UK: responses to medical treatment

Howlett T. , Willis D. , Walker G. , Wass J. , Trainer P. , UK National Acromegaly Register Investigators

UK National Acromegaly Register collects data on real-life clinical practice in 34 centres. We analysed all GH and IGF1 data to assess adequacy of control on medical treatment (Rx) with somatostatin analogs (SMS) and dopamine agonists (DA).Methods: All GH records (basal, profile or GTT) in database were correlated with IGF1, Rx, surgery (TSS) and radiotherapy (RT), then processed to derive summary data for each patient and each course of Rx. GH considere...

ea0011p855 | Thyroid | ECE2006

Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients

Agha A , Walker D , Drake WM , Chew SL , Grossman AB , Jenkins PJ , Monson JP

The effect of growth hormone (GH) replacement on thyroid function in hypopituitary patients has only been studied in small groups of children and adults with conflicting results.We aimed to define the effect and clinical significance of adult GH replacement on thyroid status in a large cohort of 243 patients with hypopituitarism due to various causes. 84 patients were considered euthyroid before GH treatment and 159 patients had central hypothyroidism an...

ea0009p111 | Endocrine tumours and neoplasia | BES2005

Dehydroepiandrosterone (DHEA) replacement enhances IGF-I generation in hypopituitary patients on growth hormone replacement

Brooke A , Kalingag N , Maher K , Walker D , Hinson J , Monson J

We have reported that serum DHEAS increases in growth hormone deficient (GHD) adults with intact ACTH reserve during GH replacement (GHR) in contrast with persisting low levels in ACTH-deficient GHD patients (Isidori et al. Clin Endo 2003:58:601). This was associated with a lower GH dose requirement in ACTH sufficient patients suggesting that DHEA may augment IGF-I generation. We have examined this hypothesis in a double blind placebo controlled trial of 30 hypopituitary femal...